Stuart Cockerill

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein

John P. DeVincenzo, Dereck Tait, John Efthimiou et al. · Antimicrobial Agents and Chemotherapy · 2019 · 88 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Stuart Cockerill, Colin Stubberfield, Jeremy N. Stables et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 80 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity

Richard Angell, Paul Bamborough, Jacky B. Buckton et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 78 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

Richard Angell, Tony D. Angell, Paul Bamborough et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 57 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12